---
title: "Raymond James Sticks to Their Sell Rating for Lancashire Holdings (LRE)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294471253.md"
description: "Raymond James analyst Ben Cohen maintained a Sell rating on Lancashire Holdings (LRE) with a $560 price target. RBC Capital's Benjamin Cohen also issued a Sell rating. Conversely, Barclays maintained a Hold rating on the stock."
datetime: "2026-07-31T07:25:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294471253.md)
  - [en](https://longbridge.com/en/news/294471253.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294471253.md)
generator: "portal-rs"
---

# Raymond James Sticks to Their Sell Rating for Lancashire Holdings (LRE)

In a report released yesterday, Ben Cohen from Raymond James maintained a Sell rating on Lancashire Holdings, with a price target of p560.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

According to TipRanks, Cohen is a 2-star analyst with an average return of 4.0% and a 33.33% success rate.

In addition to Raymond James, Lancashire Holdings also received a Sell from RBC Capital’s Benjamin Cohen in a report issued yesterday. However, on the same day, Barclays maintained a Hold rating on Lancashire Holdings (LSE: LRE).

### Related Stocks

- [LRE.UK](https://longbridge.com/en/quote/LRE.UK.md)
- [RJF.US](https://longbridge.com/en/quote/RJF.US.md)
- [RY.US](https://longbridge.com/en/quote/RY.US.md)
- [BARC.UK](https://longbridge.com/en/quote/BARC.UK.md)
- [BCS.US](https://longbridge.com/en/quote/BCS.US.md)
- [RJF-B.US](https://longbridge.com/en/quote/RJF-B.US.md)

## Related News & Research

- [Lancashire Sets Date for Q3 2026 Trading Update and Investor Call](https://longbridge.com/en/news/299906559.md)
- [Lancashire Holdings (LRE) Gets a Buy from Goldman Sachs](https://longbridge.com/en/news/294494805.md)
- [AstraZeneca strikes clinical collaboration with Summit to test ADC sonesitatug vedotin with ivonescimab in GI cancers](https://longbridge.com/en/news/300421385.md)
- [Meta vs. Microsoft: One Hyperscaler Stock Has Room to Grow, the Other Lacks a Catalyst, Says Investor](https://longbridge.com/en/news/300456248.md)
- [NVDA or AMD: Cathie Wood Buys $78.8M of One AI Stock Today, Sells the Other](https://longbridge.com/en/news/300500578.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**